Phenotypic and Genotypic Characterization of Nosocomial Isolates of Staphylococcus aureus with Reference to Methicillin Resistance
Purpose: To investigate the occurrence, species prevalence, antibacterial resistance, and molecular characteristics of S. aureus isolates from different wards located in a university hospital.
Methods: A total of one hundred and fifty S. aureus isolates were recovered from various clinical specimens. The isolates were tested phenotypically by conventional methods and genotypically by polymease chain reaction (PCR) for direct detection of femB and mecA genes.
Results: Thirty one isolates (20.7 %) of these were identified as methicillin-resistant Staphylococcus aureus (MRSA) by oxacillin agar screen test and 124 (82.7 %) of the isolates were β-lactamase producers. The prevalence of MRSA strains among S. aureus isolates was 20.7 %. The overall resistance of MRSA to a variety of antibiotics tested was linezolid, 48.7 %; ciprofloxacin, 15.3 %; sulfamethoxazole/trimethoprim (TMS), 14.0 %; gentamicin, 12.7 %; and rifampicin, 6.7 %. All MRSA isolates were positive for femB and mecA genes; one MSSA carried mecA gene.
Conclusion: Since S. aureus isolates are commonly associated with wound infections, skin and soft tissue infections and blood stream infections, glycopeptides, mupirocin, and quinupristin/dalfopristin (Q/D) would be the most effective antibiotics for the treatment of MRSA infections.
Keywords: Staphylococcus aureus, mecA, femB, Antibiotics, Staphylococcal infections, Methicillin resistance
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.